EGFR and neoplasm: In a subset of advanced colorectal cancers (CRCs), treatment of RAS wild-type (wt) tumors with the anti-EGFR antibodies cetuximab or panitumumab leads to the killing of drug-sensitive cells and tumor volume reduction [1].